Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphomic-Based vs Standard-of-Care Cefazolin Dosing for Antimicrobial Prophylaxis
NCT06005168Phase 4Completed
- Sponsor
- University of Michigan
- Start
- Mar 2023
- Primary completion
- Oct 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of cefazolin in surgical site infection (SSI), sponsored by University of Michigan. Started Mar 2023; status: completed.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT06005168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005168.